Digital Therapeutic (DTx) Market Size, Share, Forecast Report, 2026-2035

Digital Therapeutic (DTx) Market Size, Growth and Trends 2026 to 2035

The global digital therapeutic (DTx) market size was estimated at USD 6.35 billion in 2025 and is expected to reach USD 67.69 billion by 2035, growing at a CAGR of 26.7% from 2025 to 2035.

Digital Therapeutic (DTx) Market Outlook

• Market Growth Overview: The digital therapeutic (DTx) market is expected to grow significantly between 2026 and 2035, driven by the rising burden of chronic diseases, integration of advanced technology, and increasing global adoption of smartphones and internet penetration. 
• Sustainability Trends: Sustainability trends involve environmental sustainability, economic and operational sustainability, and digital ecosystem integration. 
• Major Investors: Major investors in the market include Octopus Ventures, StartUp Health, RA Capital Management, Bayer, Sanofi, and Novartis.

Digital Therapeutic (DTx) Market Report Scope

Digital Therapeutic (DTx) Market Regional Insights

By Sales Channel Insights

How did the B2B Segment Dominate the Digital Therapeutic (DTx) Market?

The B2B segment is driven by employers and payers integrating DTx into health plans to manage chronic conditions and reduce long-term costs through value-based care models. The seamless integration with Electronic Health Records (EHRs) and strategic pharmaceutical partnerships has made B2B the primary engine for clinical adoption. Collectively, these factors ensure that B2B remains the most robust and scalable pathway for delivering digital medical interventions.

How did the Pharmaceutical Companies Segment Expect to Hold the Fastest-Growing Digital Therapeutic (DTx) Market in the Coming Years?

The pharmaceutical companies segment is driven by the integration of drug-digital combinations that pair traditional medication with monitoring software. These strategic alliances between pharma and tech developers accelerate the commercialization of personalized, evidence-based treatments for chronic conditions like diabetes. By securing FDA and CE regulatory approvals, these hybrid therapies build the clinical trust necessary for widespread insurance reimbursement. 

By Application Insights

How did the Treatment/Care-Related Applications Segment Account for the Largest Share in the Digital Therapeutic (DTx) Market?

The treatment/care-related applications segment is driven by the high global prevalence of chronic conditions, such as diabetes and hypertension, that require continuous, long-term management. These digital solutions provide a cost-effective alternative to traditional care by using remote monitoring and real-time feedback to prevent expensive acute complications. Strong investment and the integration of wearable technology have further accelerated adoption by enabling highly personalized, evidence-based treatment plans.

How did the Preventive Applications Segment Expect to Hold the Fastest-Growing Digital Therapeutic (DTx) Market in the Coming Years?

The preventive applications segment is driven by strategic shift toward proactive lifestyle management for chronic diseases. Advanced technologies like AI, IoT, and wearables enable continuous, personalized monitoring that makes these interventions highly efficient and data-driven. The health systems transition to value-based care, these preventive tools serve as a critical, cost-effective mechanism for reducing long-term medical expenditures. Collaborative efforts to integrate these tools into insurance and provider workflows are further accelerating their adoption globally.

Key Players in the Digital Therapeutic (DTx) Market

• Noom: Noom contributes to the digital therapeutic market by leveraging psychology-based approaches and AI-driven coaching to facilitate sustainable behavioral changes for weight management and diabetes prevention. 
• Livongo Health: Livongo (now part of Teladoc Health) pioneered the digital therapeutics space with its "Applied Health Signals" platform, which uses cellular-connected devices to provide real-time, data-driven feedback for managing chronic conditions like diabetes and hypertension. 
• Omada Health: Omada Health provides a virtual-first care platform that integrates professional health coaching, connected devices, and personalized digital curriculum to treat chronic conditions such as type 2 diabetes, hypertension, and obesity.  
• WellDoc: WellDoc offers the BlueStar digital therapeutic platform, which is FDA-cleared and utilizes AI-driven coaching to empower individuals with type 1 and type 2 diabetes to self-manage their condition. 
• Pear Therapeutics: Pear Therapeutics led the way in prescription digital therapeutics (PDTs) by developing FDA-authorized software applications, such as reSET for substance use disorder and Pear-004 for schizophrenia, designed to be used alongside clinical care. 

The Research Report Categorizes the Digital Therapeutics Market into the Following Segments and Subsegments:

By Sales Channel

• B2C
  • Patients
  • Caregivers
• B2B
  • Providers
  • Payers
  • Employers
  • Pharmaceutical Companies
  • Other Buyers

By Application

• Preventive Applications
  • Prediabetes
  • Obesity
  • Nutrition
  • Lifestyle Management
  • Other Preventive Applications
• Treatment/Care-related Applications
  • Diabetes
  • CNS Disorders
  • Chronic Respiratory Disorders
  • Musculoskeletal Disorders
  • Cardiovascular Diseases
  • Smoking Cessation
  • Medication Adherence
  • Gastrointestinal Disorders
  • Substance Use & Addiction Management
  • Rehabilitation & Patient Care
  • Other Treatment/Care-related Applications

By Region

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe (RoE)
• APAC
  • Japan
  • China
  • India
  • Rest of the APAC
• Rest of the World (RoW)